The increasing global prevalence of cancer is fueling the demand for peptide-drug conjugates as targeted therapies, providing improved effectiveness and lower systemic toxicity than conventional ...

DelveInsight's Peptide-drug Conjugate Market Insights report provides the current and forecast market analysis, individual leading ...

Presented in partnership with the Perricelli-Gegnas Center for Entrepreneurship & Innovation, O'Leary will appear in the Weis ...

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with overall 7% growth for the year. Shares fell more than 10% as Merck paused ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Robert F. Kennedy Jr.'s nomination for US health secretary advances with crucial Republican support, despite controversy over ...

Wall Street rebounds as tech stocks surge, with the S&P 500 up 0.5% amid easing trade tensions and strong corporate earnings.

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

In 2000, the Union for International Cancer Control (UICC) named Feb. | In 2000, the Union for International Cancer Control named Feb. 4 World Cancer Day, with a goal of raising awareness of cancer ...

Merck said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak discretionary spending, a move that dented its full-year forecast and sent ...

Merck (MRK) reported fourth quarter and full-year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...